The use of benzodiazpines and related drugs amongst older people in Sweden: Associated factors and concomitant use of other psychotropics

Johnell, Kristina; Fastbom, Johan

doi:10.1002/gps.2189

Cited by 68 publications

(63 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As is the case with benzodiazepine use, the probability of a patient using zolpidem increased with age, female sex, and concomitant use of other psychotropics 17,18 ; our results confirmed this pattern. Kripke 11,19,20 has extensively studied the association between hypnotics and cancer risk, and his published work addresses this issue.…”

Section: Discussionsupporting

confidence: 79%

Relationship of Zolpidem and Cancer Risk: A Taiwanese Population-Based Cohort Study

Kao

Sun

Liang

et al. 2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective: To evaluate the relationship between the use of zolpidem and subsequent cancer risk in Taiwanese patients. Methods: We used data from the National Health Insurance system of Taiwan to investigate whether use of zolpidem was related to cancer risk. For the study cohort, we identified 14,950 patients who had received a first prescription for zolpidem from January 1, 1998, through December 31, 2000. For each zolpidem user, we selected randomly 4 comparison patients without a history of using zolpidem who were frequency-matched by sex, age, and year of the index date. Incidence rates of all cancers and selected site-specific cancers were measured by the end of 2009, and related hazard ratios (HRs) and 95% confidence intervals (CIs) of the cancer were measured as well. Results: The risk of developing any cancer was greater in patients using zolpidem than in nonusers (HR, 1.68; 95% CI, 1.55-1.82). The stratified analysis showed that the overall HR for high-dosage zolpidem (Ն300 mg/y) was 2.38. The site-specific cancer risk was the highest for oral cancer (HR, 2.36; 95% CI, 1.57-3.56), followed by kidney cancer, esophageal cancer, breast cancer, liver cancer, lung cancer, and bladder cancer (HR, 1.60; 95% CI, 1.06-2.41). Men were at higher risk than women. Conclusion: This population-based study revealed some unexpected findings, suggesting that the use of zolpidem may be associated with an increased risk of subsequent cancer. Further large-scale and in-depth investigations in this area are warranted.

show abstract

Section: Discussionsupporting

confidence: 79%

Relationship of Zolpidem and Cancer Risk: A Taiwanese Population-Based Cohort Study

Kao

Sun

Liang

et al. 2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…3,50 Similar to previous studies, 7,8,14,20,51 we found adults had increased odds of long-term sedative use if they were women, if they had low incomes and if they had relatively poor health status. We also found that having a surname of Chinese or South Asian origin was associated with a protective effect on the odds of long-term sedative use.…”

Section: Discussionsupporting

confidence: 87%

Long-term sedative use among community-dwelling adults: a population-based analysis

et al. 2017

View full text Add to dashboard Cite

“…Studies in other countries have also shown the improper, i.e., the beyond guideline, use BZD-Z by elderly. [4][5][6][7][8] Our results have shown that in Norway for most years more than half of users used well over the maximum amounts suggested by guidelines. In numbers this means that more than 70 000 Norwegians are taking excess BZD-Z annually just for this age group.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6][7][8] One would hope that after many warnings and repeated emphasis on limiting use, at least see some trend towards improvement in use would be seen. Our objectives then are to examine BZD-Z use in elderly people: Is BZD-Z use changing over the years, and, if so, is it in the direction of increased compliance with guidelines?…”

Section: Introductionmentioning

confidence: 99%

Benzodiazepine and z-hypnotic use in Norwegian elderly, aged 65-79

Berg¹

2012

Nor J Epidemiol

View full text Add to dashboard Cite

Purpose: Benzodiazepines/z-hypnotics (BZD-Z) guidelines suggest that elderly people ought to use anxiolytic benzodiazepines (BZD) and z-hypnotics only at low dose and only for a short time, and that hypnotic BZD not should be used at all. Since the elderly aged 65-79 tend to be recently retired but still in relatively good health, they may have different needs for BZD-Z than those older or younger. Our objective is to examine BZD-Z use in this age group. Methods: The study population consisted of Norwegians, aged 65-79, who filled prescriptions for anxiolytic BZD, hypnotic BZD and/or z-hypnotics in [2004][2005][2006][2007][2008][2009]. The quantities prescribed were in daily defined doses (DDD), and 100 DDD/year was deemed excessive. Results: More than a quarter of the population received at least one BZD-Z prescription each year. Half of those received more than 100 DDD/year and a quarter received over 250 DDD/year, with these proportions increasing year by year. All three subgroups of BZD-Z showed increasing use with age and all except anxiolytic BZD showed increasing proportions of users using more than 100 DDD/year with age. Conclusions: Substantial numbers of elderly aged 65-79 receive prescriptions for BZD-Z, more with increasing age, and greater amounts per user. Guidelines are clearly ignored. While a rigid enforcement of guidelines/rules is not the answer, allowing the status quo to continue shows lack of respect for guidelines.

show abstract

The use of benzodiazpines and related drugs amongst older people in Sweden: Associated factors and concomitant use of other psychotropics

Cited by 68 publications

References 41 publications

Relationship of Zolpidem and Cancer Risk: A Taiwanese Population-Based Cohort Study

Relationship of Zolpidem and Cancer Risk: A Taiwanese Population-Based Cohort Study

Long-term sedative use among community-dwelling adults: a population-based analysis

Benzodiazepine and z-hypnotic use in Norwegian elderly, aged 65-79

Contact Info

Product

Resources

About